Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Dec 1;8(1):10-6.
doi: 10.3816/CGC.2010.n.002.

The current and emerging role of immunotherapy in prostate cancer

Ravi A Madan  1 , James L Gulley
Affiliations
Review

The current and emerging role of immunotherapy in prostate cancer

Ravi A Madan et al. Clin Genitourin Cancer. .

Abstract

Recent phase III trial results have demonstrated the effectiveness of sipuleucel-T, a therapeutic cancer vaccine, in the treatment of metastatic prostate cancer. Yet, despite the survival benefit of sipuleucel-T, questions remain about how immunologic agents can be used in the treatment of metastatic prostate cancer. The primary issue confounding researchers and practitioners about the benefits of sipuleucel-T is the lack of effect on time to progression. It may be helpful to note that recent phase II data from a different therapeutic prostate cancer vaccine (Prostvac), as well as phase III data from an anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) blocking agent in metastatic melanoma, also show improved survival without short-term changes in disease progression. Furthermore, mathematical tumor growth models provide some insight into the fact that immunologic therapies do allow for continued tumor growth, but at a slower rate, thus prolonging survival. This understanding can help to clarify the role of the newly approved sipuleucel-T in the treatment of metastatic prostate cancer. It is also possible that appropriate sequencing of therapies could further improve the clinical course for such patients. Additional clinical trials will further our understanding of the role of therapeutic cancer vaccines and add new agents to the armamentarium of therapy for patients with prostate cancer.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Emerging Treatment Paradigm for Patients with Metastatic Prostate Cancer *See Table 2 for Options after Sipuleucel-T
Figure 2
Figure 2
Options After Treatment with Sipuleucel-T
See this image and copyright information in PMC

References

    1. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–12. - PubMed
    1. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513–20. - PubMed
    1. Sartor A, Oudard S, Ozguroglu M, et al. Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: final results of a multinational phase III trial (TROPIC). Presented at: ASCO Genitourinary Cancers Symposium; San Francisco, California. March 5–7, 2010; Abstract 9.
    1. FDA Approves a Cellular Immunotherapy for Men with Advanced Prostate Cancer. 2010 Apr 29; [cited June 7, 2010]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm210174.htm.
    1. Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009;324:787–90. - PMC - PubMed

Publication types